Harnessing the full potential of BH3 mimetics to treat blood cancers

利用 BH3 模拟物的全部潜力治疗血癌

• 批准号: nhmrc : GNT1156024
• 负责人: Prof David Huang
• 金额: $ 78.54万
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/harnessing-potential-bh3-blood-cancers/1349200
• 关键词: Harnessing; full; potential; BH3; mimetics

I utilise knowledge gained from basic research to improve healthcare of patients. By exploiting our knowledge of how cell survival is controlled, I led the development of a new anti-cancer drug called venetoclax, now used for chronic lymphocytic leukaemia. I will undertake studies to ascertain how it can be best used in patients with other blood cancers, and begin to develop other similar drugs. My future research seeks to markedly improve treatment for Australian patients with blood cancers.

我利用从基础研究中获得的知识来改善患者的医疗保健。通过利用我们对细胞存活是如何控制的知识，我领导开发了一种名为venetoclax的新型抗癌药物，目前用于治疗慢性淋巴细胞白血病。我将进行研究，以确定它如何最好地用于其他血癌患者，并开始开发其他类似的药物。我未来的研究旨在显著改善澳大利亚血癌患者的治疗。